@article{01GVDJ4DT11RRMBQ5M32FZE35V,
  abstract     = {{Background: The risks and impact of COVID19 disease and vaccination in patients with Immune Mediated Inflammatory Diseases (IMID) remain incompletely understood. IMID patients and particularly patients receiving immunosuppressive treatment were excluded from the original, registrational phase-3 COVID19 vaccination efficacy and safety trials. Real-world observational data can help to fill this gap in knowledge. The BELCOMID study aims to explore the interaction between IMIDs, immune-modulating treatment modalities and SARS-CoV-2 infection and vaccination in a real-life patient cohort.

Methods: A multidisciplinary, prospective, observational cohort study was set up. Consecutive patients with IMIDs of the gut, joints and skin followed at two high-volume referral centers were invited. Both patients under conventional treatment or targeted immune modulating therapies were included. Patient data and serological samples were collected at 3 predefined periods (before COVID19 vaccination, before booster vaccination, after booster vaccination). Primary endpoints were positive PCR-test and SARS-CoV-2 serology reflecting previous SARS-CoV-2 infection or vaccination. Associations with IMID treatment modality and IMID disease activity were assessed. Results of the first two inclusion periods (before booster vaccination) are reported.

Results: At the first inclusion period data was assessed of 2165 IMID-patients before COVID19 vaccination. At the second inclusion period, data of 2065 patients was collected of whom 1547 had received complete baseline COVID19 vaccination and 222 were partially vaccinated. SARS-CoV-2 infection rate remained low in both groups. No significant increase in IMID flare-up rate was noted in patients with prior SARS-CoV-2 infection. Multiple logistic regression analyses did not show a significant influence of IMID-treatment modality or IMID activity on SARS-CoV-2 infection risk (based on PCR positivity or N-serology). Patients treated with conventional immunomodulators, systemic steroids, and patients on advanced therapies such as biologics or small molecules, had reduced S-antibody seroconversion. S-antibody response was also lower in patients without prior SARS-CoV-2 infection and in active smokers. A subset of patients (4.1%) had no S- nor N-antibody seroconversion following complete baseline vaccination.

Conclusion: The BELCOMID study results confirm the benign course of COVID19 infection and vaccination in a large real-life IMID-population. However, our results underscore the need for repeated vaccination and smoking cessation in patients with IMIDs treated with immune-modulating therapies or systemic steroids during the pandemic.}},
  articleno    = {{1126351}},
  author       = {{Geldof, Jeroen and Truyens, Marie and Sabino, João and Ferrante, Marc and Lambert, Jo and Lapeere, Hilde and Hillary, Tom and Van Laethem, An and de Vlam, Kurt and Verschueren, Patrick and Padalko, Elizaveta and Lobatón Ortega, Triana and Vermeire, Séverine}},
  issn         = {{1664-3224}},
  journal      = {{FRONTIERS IN IMMUNOLOGY}},
  keywords     = {{Immunology,Immunology and Allergy,real-world data,immunomodulator,biologic,IMID,COVID19,SARS-CoV-2}},
  language     = {{eng}},
  pages        = {{13}},
  title        = {{SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders : a prospective, real-life Belgian cohort study - the BELCOMID study}},
  url          = {{http://doi.org/10.3389/fimmu.2023.1126351}},
  volume       = {{14}},
  year         = {{2023}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: